Table 7 Transfusion studies
Author | Year | Study type | Centre(s) | Number | Population | Intervention | Control | Primary outcome | Surrogate vs patient-centred | LFU (days) |
|---|---|---|---|---|---|---|---|---|---|---|
Johannson et al. [111] | 2007 | RCT | 1 | 18 | TBSA > 10% | Recombinant factor VIIa during burn E&G | Placebo | Transfusion requirement | Surrogate | 30 |
Mzezewa et al. [112] | 2004 | RCT | 1 | 51 | Adult AND paediatric (mostly adult) TBSA > 10% | Pre-op terlipressin | Placebo | Blood loss | Surrogate | NA |
Palmieri et al. [113] | 2017 | RCT | 18 | 347 | TBSA >  20% | Restrictive transfusion strategy (Hb target 70–80 g/L) | Liberal transfusion strategy (Hb target 100–110 g/L) | Number of blood stream infections | Patient-centred | 31 |
Schaden et al. [114] | 2012 | RCT | 1 | 30 | TBSA > 25% | ROTEM-guided algorithm | Standard transfusion strategy | Transfusion requirements | Surrogate | 3 |
Still et al. [115] | 1995 | RCT | 7 | 40 | TBSA 25–65% | rh-EPO | Standard care | Hb pre and post op | Surrogate | 30 |
Lundy et al. [116] | 2010 | CSWCC | 1 | 104 | TBSA > 30% | rh-EPO | Standard care | Hb pre and post op | Surrogate | > 60 |
Imai et al. [117] | 2007 | ISWCC | 1 | 14 | TBSA < 30% | Autologous PRC transfusion | Allogeneic PRC transfusion | Haematocrit | Surrogate | 14 |
Kowal-vern et al. [118] | 2000 | ISWCC | 1 | 18 | TBSA > 20% | ATIII infusion | Standard care | ATIII levels | Surrogate | 20 |